Overexpression of CD163, CD204 and CD206 on Alveolar Macrophages in the Lungs of Patients with Severe Chronic Obstructive Pulmonary DiseaseYoichiro Kaku, Tomoaki Hoshino|PLoS ONE|2014Cited by 155
FGFR1 activation is an escape mechanism in human lung cancer cells resistant to afatinib, a pan-EGFR family kinase inhibitorKoichi Azuma, Tomoaki Hoshino|Oncotarget|2014Cited by 108
Clinical significance of plasma-free amino acids and tryptophan metabolites in patients with non-small cell lung cancer receiving PD-1 inhibitor: a pilot cohort study for developing a prognostic multivariate modelKoichi Azuma, Tomoaki Hoshino|Journal for ImmunoTherapy of Cancer|2022Cited by 42
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti‐PD‐1 inhibitorNorikazu Matsuo, Tomoaki Hoshino|International Journal of Cancer|2018Cited by 38
Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapyDaiki Murata, Tomoaki Hoshino|Cancer Immunology Immunotherapy|2024Cited by 9